Innovative Product Offering Ariosa Diagnostics specializes in non-invasive prenatal testing with the Harmony(TM) test, which offers highly accurate, early genetic screening solutions that reduce reliance on invasive procedures. This presents opportunities to partner with healthcare providers seeking to upgrade prenatal care options.

Market Focus on Maternal Health The company's emphasis on maternal and fetal health positions it well for collaboration with hospitals, clinics, and maternal care centers aiming to improve diagnostic accuracy and patient outcomes in prenatal care.

Expansion and Acquisition Having been acquired by Roche in 2015 for 625 million dollars indicates strong industry validation and potential for scalability. Sales efforts can target larger healthcare systems and biotech firms interested in expanding or enhancing genetic testing portfolios.

Legal & Patent Environment Ongoing patent infringement litigation with Illumina suggests a competitive and litigious landscape. Building relationships with key industry players or offering complementary services may help mitigate risks and open new sales channels.

Technology and Data Security Utilizing established tech infrastructure like Windows Server and Microsoft IIS, Ariosa emphasizes precision analysis of cell-free DNA. Exploring opportunities around data management, security, and technology partnerships can address customer concerns around innovation and compliance.